The cardiovascular controversy
For roughly a decade, TRT prescribing was constrained by uncertainty about cardiovascular safety. Earlier observational studies had suggested possible elevated heart attack risk on TRT. The FDA added warnings, prescribing dropped, and many men with legitimate low T were left untreated due to safety uncertainty. The medical community waited for definitive data.
Earlier flawed data
The studies that raised concerns had significant limitations:
- VA cohort study had methodological issues with how outcomes were measured and assigned
- Older observational studies didn't account for confounders (men starting TRT often had multiple cardiovascular risk factors)
- Some studies used unphysiologic doses
- None were properly randomized controlled trials
Subsequent re-analyses suggested earlier concerns may have been artifactual. But the controversy required a definitive trial.
The TRAVERSE trial
Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men (TRAVERSE) was that definitive trial:
- 5,246 men aged 45-80
- Confirmed hypogonadism (T <300 ng/dL)
- High cardiovascular risk (existing CVD or multiple risk factors)
- Randomized to testosterone gel or placebo
- Mean follow-up 33 months
- Primary outcome: composite of cardiovascular death, non-fatal MI, non-fatal stroke
Trial results
- Primary outcome: TRT non-inferior to placebo (similar rates)
- Cardiovascular death: similar
- Heart attack: similar
- Stroke: similar
- Atrial fibrillation: slightly elevated (3.5% TRT vs 2.4% placebo)
- Pulmonary embolism: slightly elevated
- Acute kidney injury: similar
The primary cardiovascular safety question was resolved: TRT is not cardiovascular-harmful in men with confirmed low T.
Remaining concerns
The atrial fibrillation and PE signals warrant attention:
- Atrial fibrillation: small absolute increase; mechanism unclear
- Pulmonary embolism: usually attributed to elevated hematocrit; manageable with hematocrit monitoring
Patients at elevated AF or DVT/PE baseline risk merit careful evaluation. For most patients, these don't outweigh benefits.
What this changes
For prescribing patterns:
- Cardiovascular safety question resolved
- Men with confirmed low T and symptoms can be treated without cardiovascular concern as primary barrier
- Men with prior cardiovascular events are not automatically excluded
- Hematocrit monitoring remains important
- Routine cardiovascular monitoring (BP, lipids, ApoB) continues
For patient confidence:
- The major safety concern that worried patients and providers is settled
- TRT is no more cardiovascular-risky than placebo
- The metabolic and quality-of-life benefits proceed without cardiovascular cost
The clinical pearl: TRAVERSE was the trial the field needed. The cardiovascular safety question that limited TRT for a decade is resolved. Men with confirmed low T and symptoms can pursue treatment without that anxiety.
Bottom line
The TRAVERSE trial established TRT as cardiovascular-safe in men with confirmed low T and existing cardiovascular risk. The earlier concerns from flawed observational data are not borne out in proper randomized data. Modest atrial fibrillation and PE signals warrant monitoring but don't outweigh benefits for most patients. The cardiovascular safety question is resolved.